Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial

Oncology

Volumn 62, Issue 1, 2002, Pages 2-8

  Blackstein, Martin ^a   Vogel, C L ^c   Ambinder, R ^d   Cowan, J ^a   Iglesias, J ^b   Melemed, A ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b ELI LILLY AND COMPANY   (United States)

^c Southpoint Medical Center   (United States)

^d FLORIDA HOSPITAL   (United States)

Author keywords

First line therapy; Gemcitabine; Metastatic breast cancer; Monotherapy; Phase II

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; INFECTION; LIVER METASTASIS; LUNG DISEASE; LUNG FUNCTION; LUNG METASTASIS; LYMPH NODE METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PAIN MEASUREMENT; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036159859     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048240     Document Type: Article

References (20)

1. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
2. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
4. The role of gemcitabine in the treatment of other tumours
5. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
6. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
7. Advanced breast cancer: A phase II trial with gemcitabine
8. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
9. Population pharmacokinetic analyses: Effect of age, gender, duration of infusion, and body surface area on gemcitabine pharmacokinetics
10. Single-agent gemcitabine is active in previously treated metastatic breast cancer
11. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial
12. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
13. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial
14. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy
15. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older
16. Carboplatin in the treatment of advanced breast cancer: A phase II study using a pharmacokinetically guided dose schedule
17. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer
18. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma
19. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients